Latest Dividends News

Earlypay Ltd reported a 31% rise in statutory net profit after tax for FY25, driven by growth in equipment finance despite declines in invoice and trade finance. The company declared a fully franked final dividend of 0.65 cents per share and outlined plans to expand its lending portfolios and streamline technology.

Kip McGrath Education Centres reported solid FY25 growth in revenue and EBITDA from continuing operations, marked by a strategic exit from the USA and a new share buy-back program.

SKS Technologies has delivered a remarkable 92% revenue surge in FY25, driven by its data centre strategy and traditional business growth, while expanding bank facilities and forecasting $300 million revenue for FY26.

SKS Technologies Group Limited has reported a remarkable 112% increase in net profit for the financial year ended June 2025, alongside a near doubling of revenue. The company also declared fully franked dividends, signaling confidence in its financial health.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Tribeca Global Natural Resources Limited (ASX – TGF) has declared a fully franked 5-cent dividend for FY25 alongside a 10% on-market buyback, while delivering returns that outpaced major natural resource indices. The company’s portfolio is well positioned to benefit from rising strategic demand for critical and precious metals amid evolving global market dynamics.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Mader Group has delivered record FY25 results with revenue climbing 13% to $872.2 million and net profit rising 13%, setting the stage for a $1 billion revenue target in FY26.